Cargando…
Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study
BACKGROUND/AIM: Sorafenib is the first systemic therapy for the treatment of advanced-stage hepatocellular carcinoma (HCC) and progressive HCC after locoregional therapy. The aim of this study was to evaluate the prognostic factors of long-term survivors after sorafenib treatment. METHODS: This mult...
Autores principales: | Cho, Young Youn, Yu, Su Jong, Lee, Hye Won, Kim, Do Young, Kang, Wonseok, Paik, Yong-Han, Sung, Pil Soo, Bae, Si Hyun, Park, Su Cheol, Doh, Young Seok, Kim, Kang Mo, Jang, Eun Sun, Kim, In Hee, Kim, Won, Kim, Yoon Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219232/ https://www.ncbi.nlm.nih.gov/pubmed/34169044 http://dx.doi.org/10.2147/JHC.S304439 |
Ejemplares similares
-
A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC
por: Lee, Jaejun, et al.
Publicado: (2020) -
Follicular and Hurthle cell carcinoma of the thyroid in iodine-sufficient area: retrospective analysis of Korean multicenter data
por: Kim, Won Gu, et al.
Publicado: (2014) -
An assessment of quality of life for early phase after adjuvant radiotherapy in breast cancer survivors: a Korean multicenter survey (KROG 14–09)
por: Rim, Chai Hong, et al.
Publicado: (2017) -
Multicenter Retrospective Analysis of the Effectiveness and Safety of Rituximab in Korean Patients with Refractory Systemic Lupus Erythematosus
por: Bang, So-Young, et al.
Publicado: (2012) -
Development of second primary cancer in Korean breast cancer survivors
por: Jung, Hong Kyu, et al.
Publicado: (2017)